The aim of this study was to evaluate the detection efficiency of 111In-PSMA-I&T SPECT/CT in comparison to hybrid 68Ga-PSMA HBED-CC PET in patients with early recurrent prostate cancer.Methods
Twenty-two patients (mean age, 68.2 ± 6.8 years; range, 52–76 years) with rising prostate-specific antigen (PSA; median, 1.03 ng/mL; range, 0.2–7.2ng/mL) and known positive lesions in hybrid 68Ga-PSMA HBED-CC PET scheduled for salvage surgery were included. Whole-body scintigraphy and SPECT/CT were performed 4 hours after application of 147.0 ± 24.8 MBq (range, 90–183 MBq) 111In-PSMA I&T. Images were evaluated for suspected lesions, and conspicuity of all lesions was rated using a 4-point-scale (0 = not seen, 1 = retrospectively seen in knowledge of 68Ga-PSMA HBED-CC PET, 2 = low signal, 3 = high signal). Tumor-to-background ratios were determined for SPECT and PET and compared. Tumor-to-background ratio of SPECT was correlated with lesion size as well as patients’ Gleason score and PSA level.Results
111In-PSMA I&T SPECT/CT detected 14 of 29 PET-positive lesions (48.3%) with no additional lesions identified with 111In-PSMA I&T SPECT/CT. There was a significant weak to moderate correlation of PSA level with tumor-to-background ratio of 111In-PSMA I&T SPECT/CT (correlation coefficient r = 0.6406; 95% confidence interval, 0.1667–0.8741; P = 0.0136). There was no significant difference (P > 0.05), but a weak trend toward a higher detectability in 111In-PSMA I&T SPECT/CT regarding lesion size and initial PSA level.Conclusions
In a preselected collective of recurrent prostate cancer patients with low PSA values, 111In-PSMA I&T SPECT/CT showed lower detection rates than hybrid 68Ga-HBED-CC PSMA PET. However, 111In-PSMA I&T SPECT/CT showed a patient based detection rate of 59%, making it a potentially valuable imaging tool where PET is not available apart from its proven value as a PSMA-targeted probe for radioguided surgery.